Bio-resorbable medical implants

Abbott Laboratories, Meril Life science Pvt. Ltd., REVA Medical and Xeltis Inc. are among the companies working on bio-resorbable implants. Their activity includes vascular scaffolds and polymeric vascular implants. BellaSeno GmbH develops 3D-printed resorbable scaffolds for breast reconstruction, while companies such as Stryker and Zimmer Biomet appear among the organizations active in orthopedic fixation and reconstruction.

BellaSeno GmbH, Xeltis Inc. and Fibrothelium GmbH are named startups working on bio-resorbable implant technologies. BellaSeno develops 3D-printed scaffolds for breast reconstruction, Xeltis develops polymeric vascular implants intended to support tissue restoration, and Fibrothelium works with silk-derived materials. Their technologies target different applications, so their progress should be assessed against application-specific clinical evidence and development milestones.

Peking University, Beihang University and Capital Medical University are among the research organizations active in this field. Peking University researchers have reported work on zinc- and magnesium-based alloys and a 3D-printed cranial device. Beihang University contributes research on zinc-alloy designs, while Capital Medical University contributes clinical evidence and guidance on absorbable polymer screws and vascular scaffolds.

The funding data lists $62,539,259 across 71 grants since 2020. This figure represents grants recorded for the field and is distinct from private financing rounds. The funding-round data includes a $52,695,000 debt and equity financing record for Xeltis Inc. dated December 2025; individual records should be checked for relevance before treating them as implant-specific investment.

Boston Scientific Scimed leads the listed patent holders with 13 patents in the dataset, followed by Ocular Therapeutix with 11 and Tepha Inc with 8. Allergan, Inc. is listed with 6, and the University Of Pittsburg Of The Commonwealth System Of Higher Education with 5. These figures identify the leading holders in the supplied patent-holder data, not the total patent portfolios of each organization.

Patent activity declined by 47.4% in the last 12 months compared with the previous 12 months, while publications grew by 14.4%. That contrast suggests research output remains active even as recent patenting has slowed. The figures describe activity across the defined window and do not establish whether individual materials or applications are gaining or losing commercial value.

Recent developments include REVA Medical’s October 2026 report of a MOTIV vascular-scaffold live-case demonstration and late-breaking BTK trial results. In August 2026, researchers reported a 3D-printed biodegradable cranial device designed for bone repair and healing assessment. Recent studies also explore coatings to regulate magnesium degradation, biodegradable electrochemical sensors and implants that combine resorption with therapeutic or diagnostic functions.

The approaches include resorbable polymers, resorbable metals, calcium phosphate ceramics, hydrogels and soft biomaterials, and composites. Polymers offer design flexibility, while metals can provide stronger temporary support; ceramics are suited to bone applications, and hydrogels to soft tissue or local delivery. Composites combine properties, but each approach brings trade-offs in strength, degradation control, tissue response or manufacturing.

The United States leads the listed countries with 13,277 documents, followed by China with 5,317 and Germany with 5,046. The United Kingdom, Japan and India are also active. These document counts indicate the distribution of recorded research and industry activity; they do not measure clinical adoption, manufacturing capacity or the quality of individual programs.

The listed applications include cardiovascular devices, orthopedic fixation, craniofacial and dental reconstruction, soft-tissue reconstruction, and neural repair and local therapy. Examples in recent research include vascular scaffolds, absorbable screws, cranial devices, reconstruction membranes and biodegradable implants for neuromodulation or local drug delivery. The design requirements differ by use, particularly in the level and duration of mechanical support needed.